Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment (Q89587297)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32030685 AND SRC:MED&resulttype=core&format=json

6 April 2020

review article

1 reference

title

Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32030685 AND SRC:MED&resulttype=core&format=json

6 April 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32030685 AND SRC:MED&resulttype=core&format=json

6 April 2020

Fabiana Conciatori

2

1 reference

ORCID Public Data File 2021

author name string

Chiara Bazzichetto

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32030685 AND SRC:MED&resulttype=core&format=json

6 April 2020

Ludovica Ciuffreda

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32030685 AND SRC:MED&resulttype=core&format=json

6 April 2020

publication date

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32030685 AND SRC:MED&resulttype=core&format=json

Advances in Experimental Medicine and Biology

6 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32030685 AND SRC:MED&resulttype=core&format=json

6 April 2020

volume

1223

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32030685 AND SRC:MED&resulttype=core&format=json

6 April 2020

page(s)

69-80

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32030685 AND SRC:MED&resulttype=core&format=json

mTOR Cross-Talk in Cancer and Potential for Combination Therapy.

6 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

mTOR signaling in growth control and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

TOR complex 2: a signaling pathway of its own.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

mTOR complex 2 signaling and functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

mTOR Signaling in Growth, Metabolism, and Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Role of mTOR Signaling in Tumor Microenvironment: An Overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

31 March 2020

TOR in the immune system

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Tumor-associated stromal cells as key contributors to the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

31 March 2020

Fibroblasts in cancer

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Origins of CD4( ) effector and central memory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4 T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4 T

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

The AKT-mTOR axis regulates de novo differentiation of CD4 Foxp3 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Regulation of T cells by mTOR: the known knowns and the known unknowns

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

mTOR Regulation of Glycolytic Metabolism in T Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

The mTOR kinase determines effector versus memory CD8 T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8 T-cell differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Accessories to the crime: functions of cells recruited to the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Rapamycin unbalances the polarization of human macrophages to M1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

mTORC2 signalling regulates M2 macrophage differentiation in response to helminth infection and adaptive thermogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

The Role of Angiogenesis in Cancer Treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Hypoxia-Induced Angiogenesis: Good and Evil

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Macrophage-Induced Tumor Angiogenesis Is Regulated by the TSC2–mTOR Pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Activation of a metabolic gene regulatory network downstream of mTOR complex 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

mTORC1 and mTORC2 in cancer and the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

PD-1 Checkpoint Blockade in Combination with an mTOR Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Tumor-secreted dickkopf2 accelerates aerobic glycolysis and promotes angiogenesis in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Combination cancer immunotherapies tailored to the tumour microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Role of the immunosuppressive microenvironment in immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Tumor microenvironment and myeloid-derived suppressor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

A core of kinase-regulated interactomes defines the neoplastic MDSC lineage

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

The blockade of immune checkpoints in cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

PD-L1 expression in triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Rapamycin in transplantation: a review of the evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

mTOR inhibition improves immune function in the elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8 T cell priming to promote memory formation and metabolic readiness

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-030-35582-1_4

10.1007/978-3-030-35582-1_4

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32030685 AND SRC:MED&resulttype=core&format=json

6 April 2020

1 reference